Medication-induced Acute dystonia is a sudden, often painful sustained muscle contraction precipitated by dopamine-receptor-blocking agents, most often within hours to days of initiation or dose escalation. The reaction is included in DSM-5-TR under medication-induced movement disorders and in ICD-11 under disorders due to substances or known physiological condition. Although the disorder is benign in most adult patients, laryngeal and pharyngeal involvement can be airway-threatening, and oculogyric crisis is profoundly distressing. Anticholinergic or antihistaminic reversal is rapid and gratifying when the diagnosis is correct. The bottom line: any new abnormal sustained posture in a patient recently exposed to a Dopamine antagonist is acute dystonia until proven otherwise.

Acute dystonia is one of the most frequent Extrapyramidal symptoms of First-generation antipsychotic agents and remains common with high-potency Second-generation antipsychotic agents. The reaction concentrates in young men receiving high-potency dopamine blockers, and onset clusters within the first 96 hours of exposure.^[1-2]

Incidence and timing

• Reported incidence with high-potency first-generation antipsychotics ranges from 10% to over 30% depending on agent, dose, and population studied.^[1-2]
• Roughly 50% of reactions occur within 48 hours of exposure and approximately 90% within 5 days; onset beyond 7 days should prompt reconsideration of the diagnosis.^[1,3]
• Lower incidence is seen with low-potency first-generation agents and most second-generation antipsychotics, though haloperidol, fluphenazine, and risperidone retain meaningful risk.^[2-3]

Demographic risk factors

• Young age: children and adolescents have the highest rates, and risk decreases progressively after age 40.^[1-2]
• Male sex: men have roughly twice the risk of women, an effect that persists after controlling for dose.^[1-2]
• Personal or family history of dystonic reactions, recent cocaine use, dehydration, and hypocalcemia each raise risk.^[2-3]

Drug-specific risk

• Highest: haloperidol 2-10 mg IM, fluphenazine 2.5-10 mg IM, and other high-potency D2 blockers.^[2-3]
• Intermediate: risperidone 2-6 mg PO QD, olanzapine at higher doses, and the antiemetics metoclopramide 10 mg IV and prochlorperazine 10 mg IV.^[3-4]
• Lower: quetiapine, clozapine, and aripiprazole, though acute dystonia is documented with each.^[3,5]

The reaction is driven by abrupt blockade of striatal D2 receptors, which unbalances striatal output and produces sustained, involuntary co-contraction of agonist and antagonist muscle groups. The classical model emphasizes a relative cholinergic excess in the Nigrostriatal pathway after dopamine receptor blockade.^[3,6]

Neurochemistry

• Postsynaptic D2 blockade in the dorsal striatum disinhibits cholinergic interneurons, producing a transient dopamine-acetylcholine imbalance favoring cholinergic tone.^[3,6]
• Paradoxically, peak risk occurs as plasma drug levels are falling, suggesting compensatory presynaptic dopamine release that briefly overshoots residual receptor blockade.^[3,6]
• Anticholinergic and antihistaminic agents reverse symptoms by restoring the cholinergic-dopaminergic balance at the striatum.^[3,6]

Pharmacology that predicts risk

• High D2 affinity with low intrinsic anticholinergic activity (haloperidol, fluphenazine) carries the highest risk.^[2-3]
• Agents with substantial muscarinic blockade (chlorpromazine, olanzapine, clozapine) self-protect against dystonia.^[3,5]
• Partial D2 agonists (aripiprazole, brexpiprazole, cariprazine) carry lower but non-zero risk, with case reports of acute dystonia particularly with rapid titration.^[5]

Imaging and circuits

• Functional imaging during dystonic episodes implicates the basal ganglia-thalamocortical motor loop, with secondary involvement of premotor cortex.^[6]
• Structural imaging is typically unremarkable; abnormal imaging should redirect the differential toward primary or secondary dystonia.^[6-7]

Genetic and individual susceptibility

• CYP2D6 poor-metabolizer status increases plasma concentrations of risperidone, haloperidol, and aripiprazole and is associated with higher extrapyramidal symptom burden.^[8]
• A personal history of dystonic reaction is the strongest single predictor of recurrence on rechallenge.^[2-3]

DSM-5-TR codes the condition as medication-induced acute dystonia within the chapter on medication-induced movement disorders and other adverse effects of medication. The diagnostic threshold is clinical: an abnormal sustained posture or muscle spasm temporally related to the start, dose increase, or recent cessation of a withdrawal-protective anticholinergic.^[9]

Core diagnostic features

• Abnormal and sustained posture or spasm of the eyes, head, neck, limbs, or trunk developing within days of starting, raising the dose of, or reducing the anticholinergic protection against a dopamine-receptor-blocking medication.^[9]
• The disturbance causes clinically significant distress or impairment, or carries a risk of airway compromise.^[9]
• Symptoms are not better explained by a primary movement disorder, catatonia, seizure, conversion disorder, or general medical condition.^[9]

ICD-11 placement

• ICD-11 classifies the reaction under "acute dystonia due to psychoactive substance use" within disorders due to substance use, with a parallel adverse-effect code under chapter 24 for medication-induced disorders.^[10]
• Clinically meaningful difference: ICD-11 separates substance-induced movement disorders from idiopathic dystonia at the chapter level, which is useful for billing and surveillance but does not change bedside management.^[10]

Specifiers and course modifiers

• DSM-5-TR does not assign formal severity specifiers but recognizes a continuum from focal (e.g., torticollis) to generalized involvement.^[9]
• Onset specifier in practice: within hours of an IM injection, within the first 96 hours of oral initiation, or within days of a dose increase.^[1,9]
• Recurrence on rechallenge with the same agent is the rule rather than the exception unless prophylactic anticholinergic cover is in place.^[3]

Acute dystonia presents as the abrupt onset of sustained, twisting, or fixed postures that the patient cannot voluntarily release. Symptoms wax and wane, may shift between body regions, and characteristically distress the patient and the witnessing team alike.^[1,3]

Common topographic patterns

• Cervical: Torticollis, Retrocollis, or anterocollis with painful neck contortion.^[1,3]
• Ocular: Oculogyric crisis with sustained upward or lateral deviation of the eyes, often with associated anxiety, autonomic arousal, and obsessive thinking during the episode.^[1,11]
• Oromandibular: trismus, jaw protrusion, forced tongue protrusion, dysarthria, and dysphagia.^[1,3]
• Pharyngeal and laryngeal: choking, stridor, dysphonia, and rare but reported respiratory compromise.^[1,12]
• Truncal and limb: Opisthotonos, scoliotic posturing, and axial extension; classic in children and young men.^[1,3]

Tempo and natural history

• Onset is typically within 24-96 hours of exposure, with peak risk in the first 48 hours.^[1,3]
• Untreated episodes wax and wane over hours and usually self-resolve within 24-48 hours of stopping the offending agent, though depot injections prolong the time course markedly.^[1,3]
• Patients remain alert and oriented throughout the episode, which helps distinguish dystonia from seizure or delirium.^[1,3]

Red flags requiring immediate action

• Stridor, dyspnea, drooling, or inability to handle secretions suggest laryngopharyngeal involvement and warrant emergent reversal and airway readiness.^[12]
• Fever, rigidity, autonomic instability, and altered mental status suggest NMS rather than isolated dystonia.^[13]

The differential rests on the temporal link to a dopamine blocker and the absence of features pointing elsewhere. Several mimics carry different management implications and must be ruled out before settling on the diagnosis.^[1,3]

Other medication-induced movement disorders

• Akathisia: subjective restlessness without sustained posture; relieved by movement, not by anticholinergics.^[3,14]
• Drug-induced parkinsonism: bradykinesia, rigidity, and resting tremor developing over weeks, not hours.^[3]
• Tardive dyskinesia: choreoathetoid movements emerging after months to years of exposure; worsened, not improved, by anticholinergics.^[3,14]
• Tardive dystonia is anticholinergic-responsive but emerges late and persists after drug discontinuation, unlike acute dystonia.^[14]

Neurologic mimics

• Focal seizure: rhythmic clonic movement, altered awareness, and post-ictal state distinguish seizure from sustained dystonic posture.^[7]
• Primary dystonia: insidious onset, often task-specific (writer's cramp, musician's dystonia), no temporal link to a dopamine blocker.^[6-7]
• Wilson disease: dysarthria, tremor, Kayser-Fleischer rings, abnormal liver enzymes, and low ceruloplasmin in a young patient with new movement disorder.^[7]
• Stroke and basal ganglia lesions: focal neurologic findings, abnormal imaging.^[7]

Psychiatric and functional mimics

• Catatonia: waxy flexibility, mutism, posturing, and response to lorazepam challenge; can coexist with dystonia and complicates antipsychotic use.^[13]
• Functional movement disorder: distractibility, suggestibility, incongruent patterns, and absence of medication trigger.^[7]
• Conversion symptoms after antipsychotic exposure are uncommon and remain a diagnosis of exclusion.^[7]

Metabolic and toxic mimics

• Hypocalcemia and hypomagnesemia produce carpopedal spasm and tetany; check ionized calcium when in doubt.^[7]
• Strychnine poisoning and tetanus produce generalized rigidity with preserved consciousness and warrant ED-level workup if the temporal link to a dopamine blocker is absent.^[7]
• Serotonin syndrome: clonus, hyperreflexia, autonomic instability, and a serotonergic exposure history rather than a dopamine blocker.^[14]

Assessment is bedside and time-sensitive: confirm exposure to a dopamine blocker, characterize the movement, and exclude airway compromise or NMS before anything else. Diagnostic delay is the most common avoidable harm.^[1,12]

Mandatory history

• Exact medication, dose, route, and timing of most recent administration, including depot injections in the prior month.^[1,3]
• Antiemetic exposure in the prior 72 hours (metoclopramide, prochlorperazine, promethazine) — frequently missed history element.^[4]
• Prior dystonic reactions, family history of dystonic reactions, and any anticholinergic cover already prescribed.^[2-3]
• Substance use, particularly cocaine and stimulants, which independently raise dystonia risk.^[2]

Targeted examination

• Document the involved muscle groups, sustained versus intermittent character, and provoking or relieving maneuvers.^[1,3]
• Examine airway, voice, and ability to handle secretions before any other diagnostic step.^[12]
• Check vital signs and temperature to screen for NMS; rigidity outside the dystonic posture and hyperthermia change the algorithm.^[13]

Rating instruments

• The Extrapyramidal Symptom Rating Scale (ESRS) and the Simpson-Angus Scale include dystonia subscales useful for serial documentation.^[15]
• The Burke-Fahn-Marsden Dystonia Rating Scale is the standard for primary dystonia and is occasionally used in research on tardive dystonia; it is overkill for acute reactions.^[15]

Labs and imaging — what to do, and what not to:

• Send creatine kinase, basic metabolic panel including calcium and magnesium, and a pregnancy test in those of reproductive potential.^[7,13]
• Obtain an EKG before any high-dose IV diphenhydramine or further antipsychotic dosing if not already on file.^[14]
• Neuroimaging is not required for a textbook acute dystonic reaction; reserve for atypical features, focal neurologic signs, or failure to respond to anticholinergic challenge.^[6-7]
• Drug levels and CYP2D6 genotyping are not part of acute management; consider after recurrent reactions to guide future prescribing.^[8]

Acute dystonia responds rapidly to parenteral anticholinergic or antihistamine therapy, and prevention of recurrence is as important as the acute reversal. The clinical bottom line is to dose parenterally for an active reaction, then bridge to oral cover while reassessing the offending agent.^[15-16]

Pharmacotherapy

• First-line acute reversal is benztropine 1-2 mg IM or diphenhydramine 25-50 mg IM, with onset of relief in 15-30 minutes.^[15-16]
• Repeat the dose at 20-30 minutes if no response; reconsider the diagnosis if no improvement after two adequate doses.^[15-16]
• For severe or laryngeal involvement, IV administration of diphenhydramine 50 mg or benztropine 1-2 mg gives faster onset with comparable efficacy.^[12,15]
• Bridge to oral anticholinergic cover for 7-14 days after the acute episode, typically benztropine 1-2 mg PO BID or trihexyphenidyl 2-5 mg PO BID, given that the offending agent often must be continued.^[15-16]
• Benzodiazepines (lorazepam 1-2 mg IM or IV) are useful adjuncts when anticholinergics are contraindicated or partially effective.^[15]

Psychotherapy

• Psychotherapy plays no acute role; supportive counseling and psychoeducation about future medication exposures reduce anxiety on subsequent prescribing.^[16]
• Document the reaction prominently in the medical record and discuss avoidance of high-potency D2 blockers with the patient and family.^[16]

Neuromodulation

• No role for ECT, rTMS, or DBS in acute dystonic reactions.^[15-16]
• DBS targeting the globus pallidus internus has a role in refractory primary and tardive dystonia but not in self-limited drug-induced acute reactions.^[6]

Adjunctive

• Switch the offending agent to a lower-risk antipsychotic where clinically appropriate; quetiapine, olanzapine, and clozapine carry lower acute dystonia risk than haloperidol or fluphenazine.^[3,5]
• For patients who must continue a high-potency agent, prophylactic oral anticholinergic cover for the first 1-3 months reduces recurrence; routine indefinite prophylaxis is not recommended because of cognitive and anticholinergic burden.^[15-16]
• Treat any contributing dehydration, hypocalcemia, or hypomagnesemia.^[7]
• Counsel patients on stimulant and cocaine avoidance during ongoing antipsychotic treatment.^[2]

The harms of acute dystonia itself are dominated by airway risk and by the psychological aftermath of a frightening, painful episode that often arrives within the first day of treatment. The harms of treatment are anticholinergic and sedative.^[12,15-16]

Common adverse effects of treatment

• Sedation, dry mouth, blurred vision, constipation, and urinary hesitancy with both benztropine and diphenhydramine.^[15-16]
• Tachycardia and mild cognitive impairment, particularly problematic in patients with baseline cognitive vulnerability.^[15-16]
• Patient-reported dislike of anticholinergic side effects contributes to nonadherence with oral cover.^[16]

Serious or rare adverse effects

• Anticholinergic delirium with hyperthermia, agitation, and urinary retention; risk rises sharply with concomitant antimuscarinic agents and in older adults.^[16]
• Acute angle-closure glaucoma in predisposed eyes after anticholinergic dosing.^[16]
• Aspiration during prolonged untreated pharyngeal dystonia.^[12]
• Rare reports of cardiovascular collapse with high-dose IV diphenhydramine in patients with prolonged QT.^[14]

Monitoring, withdrawal, and discontinuation

• After acute reversal, reassess mental status, vital signs, and ability to swallow before transferring or discharging.^[15]
• Plan a structured taper of oral anticholinergic cover after 1-3 months; abrupt discontinuation can unmask latent EPS.^[16]
• Document the reaction in problem lists and allergy-style alerts to prevent future inadvertent rechallenge with the same agent.^[16]

Limitations of the evidence base

• Most evidence predates current second-generation antipsychotic prescribing and the partial-agonist era; head-to-head RCT data are sparse.^[16]
• Pediatric and perinatal data are largely observational; case-report bias likely overstates dramatic presentations and understates milder reactions.^[1,17]
• Underreporting of antiemetic-induced dystonia in emergency department datasets distorts incidence estimates.^[4]

Risk profile and acceptable interventions vary meaningfully by age, pregnancy status, and comorbid burden. Tailoring the approach is more important than memorizing a single algorithm.^[16-17]

Pediatric and adolescent

• Highest incidence per exposure; reactions after a single antiemetic dose are well described.^[1,4]
• diphenhydramine 1 mg/kg IV up to 50 mg is the typical first-line agent because of familiarity and pediatric dosing data.^[15,17]
• Pediatric reactions raise the threshold for ongoing exposure; involve pediatric neurology when reactions are atypical.^[17]

Geriatric

• Lower per-exposure rate of acute dystonia but markedly higher risk of anticholinergic delirium and falls from treatment.^[16]
• Prefer benztropine 0.5-1 mg IM over diphenhydramine when feasible, and avoid repeat dosing without clear ongoing dystonia.^[15-16]
• Reassess all anticholinergic medications and consider switching to a lower-EPS antipsychotic rather than adding chronic cover.^[16]

Perinatal

• Pregnancy and the immediate postpartum period are periods of heightened antipsychotic prescribing for psychotic and mood disorders; acute dystonia remains a concern.^[17]
• Benztropine and diphenhydramine are both used; diphenhydramine has more reassuring human pregnancy data.^[17]
• Neonatal extrapyramidal symptoms have been reported after third-trimester exposure to antipsychotics; the obstetric and pediatric team should be aware.^[17]

Comorbid medical illness

• Glaucoma, prostatic hypertrophy, gastroparesis, and severe constipation are relative contraindications to anticholinergic reversal; consider IV diphenhydramine or lorazepam adjunct.^[15-16]
• HIV-associated dementia and other basal ganglia-vulnerable conditions raise baseline EPS risk; titrate D2 blockers slowly and prefer lower-affinity agents.^[18]

Comorbid substance use

• Cocaine and other stimulants potentiate dystonic reactions; obtain a urine toxicology screen if the temporal link to the antipsychotic is uncertain.^[2]
• Alcohol withdrawal can mimic akathisia and tremor; the two conditions can coexist with acute dystonia and require simultaneous management.^[14]

Cultural considerations

• Oculogyric crisis is sometimes misinterpreted as possession or seizure in cultures where antipsychotic familiarity is low; psychoeducation in the patient's first language reduces stigma and improves future adherence.^[16]

Prognosis is excellent with prompt recognition and reversal, and the great majority of patients tolerate ongoing antipsychotic therapy with appropriate adjustments. Recurrence is the dominant long-term issue.^[3,16]

Natural history

• With treatment, symptoms resolve within minutes to hours; without treatment, episodes typically remit within 24-48 hours after the offending agent is cleared, though depot formulations prolong the course for days to weeks.^[1,3]
• A single episode does not predict tardive dystonia or other late-onset movement disorders.^[3,14]

Recurrence and rechallenge

• Rechallenge with the same agent without anticholinergic cover produces recurrence in the majority of cases.^[3]
• Switching to a lower-D2-affinity agent reduces but does not eliminate recurrence; prophylactic cover further reduces risk.^[3,16]

Functional outcome

• Most patients have no long-term functional sequelae from an isolated acute dystonic reaction.^[3,16]
• A traumatic first reaction is a leading reported reason for antipsychotic nonadherence; this is the most consequential long-term harm and is preventable with anticipatory counseling.^[16]

Mortality

• Mortality from acute dystonia is rare and almost entirely attributable to airway compromise or to misdiagnosis as another condition with delayed treatment.^[12]

Acute dystonia is a psychiatric emergency in two specific situations: when the airway is involved, and when the diagnosis is wrong. The bedside priority is to exclude NMS, secure the airway if pharyngeal involvement is present, and then reverse pharmacologically.^[12-13]

Airway management

• Laryngeal involvement presents with stridor, dysphonia, or dyspnea and demands immediate parenteral anticholinergic administration and airway readiness.^[12]
• Prepare suction, bag-valve-mask ventilation, and a definitive airway pathway; intubation is rarely required if reversal is timely.^[12]
• IV access and continuous monitoring are warranted until pharyngeal function is fully restored and the patient can manage secretions independently.^[12]

Disposition

• After uncomplicated reversal, observation for 4-6 hours in a monitored setting is reasonable; depot exposure or recurrent symptoms warrant longer monitoring.^[15]
• Hospitalization is indicated for laryngeal involvement, suspected NMS, repeated reactions, or unstable comorbid medical illness.^[12-13]
• Outpatient prescribers should be notified at discharge with explicit instructions about anticholinergic cover and recommended agent changes.^[16]

Safety planning

• Document the reaction in the chart as a medication-induced movement disorder, not as an allergy; the patient may need the same class again under different circumstances.^[16]
• Provide the patient with a wallet card or chart alert naming the offending agent and the successful reversal regimen.^[16]
• Review every antiemetic and antipsychotic the patient is prescribed at every transition of care; metoclopramide and prochlorperazine are common silent contributors.^[4]

Most of the controversy around acute dystonia concerns prevention rather than acute treatment. Reasonable clinicians disagree about prophylaxis, drug selection, and the role of newer dopamine partial agonists.^[3,16]

Routine prophylaxis at antipsychotic initiation

• Some guidelines and Cochrane-level reviews support short-course prophylactic anticholinergic in high-risk groups; others discourage it because of anticholinergic burden in patients who will never develop dystonia.^[16]
• The middle position recommends individualized prophylaxis for young men receiving high-potency first-generation antipsychotics or rapid neuroleptization.^[3,16]

Diphenhydramine versus benztropine

• Emergency-medicine literature favors diphenhydramine for availability and pediatric familiarity; psychiatric literature favors benztropine for purer anticholinergic profile.^[15]
• Head-to-head data are limited and predate current dosing patterns; either is reasonable as first-line.^[15]

Second-generation and partial-agonist agents

• Aripiprazole, brexpiprazole, and cariprazine were initially marketed as low-EPS, yet post-marketing reports describe acute dystonia and akathisia at meaningful rates, particularly during titration.^[5,18]
• The notion of an EPS-free antipsychotic remains aspirational; comparative ranking continues to evolve.^[5]

Antiemetic-induced dystonia

• Metoclopramide carries a U.S. Food and Drug Administration boxed warning for tardive dyskinesia and is a frequent cause of acute dystonia, yet remains heavily prescribed in primary care and emergency settings.^[4]
• Whether prochlorperazine and promethazine should be similarly restricted is debated; current practice varies by region.^[4]

Misdiagnosis as conversion disorder

• A persistent clinical hazard, especially for oculogyric crisis and pure laryngeal dystonia, where the dramatic presentation and rapid reversal can be misread as functional.^[8]
• The diagnostic test is anticholinergic reversal, not psychiatric reattribution.^[8,15]

• Acute dystonia onset is typically within 24-96 hours of starting or escalating a dopamine-receptor-blocking agent.^[1,3]
• Highest-risk demographic: young men receiving high-potency first-generation antipsychotics; cocaine use further potentiates risk.^[1-2]
• Oculogyric crisis is a forced sustained upward deviation of the eyes and is a classic acute dystonia presentation.^[7]
• Laryngeal dystonia is the airway-threatening variant and requires immediate parenteral anticholinergic and airway readiness.^[12]
• First-line acute treatment is IM benztropine 1-2 mg or IM diphenhydramine 25-50 mg, with onset within 15-30 minutes.^[15-16]
• Metoclopramide is the most commonly missed nonpsychiatric cause of acute dystonia in clinical practice.^[4]
• The cardinal differential is from akathisia (inner restlessness, no sustained posture) and NMS (rigidity, fever, autonomic instability).^[3,13]
• Tardive dyskinesia is choreiform and emerges after months of exposure; acute dystonia is sustained and emerges within days.^[14]
• Recurrence after rechallenge with the same agent is the rule, not the exception; plan prophylactic anticholinergic cover or switch agents.^[3,16]
• Oral anticholinergic cover after acute reversal is typically maintained for 1-3 months and then tapered while monitoring for re-emergence.^[16]
• Document the reaction as a medication-induced movement disorder, not as a drug allergy, to preserve future therapeutic options.^[16]
• DSM-5-TR codes acute dystonia under medication-induced movement disorders; ICD-11 places it under disorders due to substances or known physiological condition.^[9-10]

No external funding. No conflicts of interest declared. Peer-review status: pending.